{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:21:39Z","timestamp":1777792899181,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Interdisciplinary tumor boards (ITB) are essential in optimizing treatment recommendations for metastatic castration-resistant prostate cancer (mCRPC) by incorporating oncology guidelines, clinical trials, and patient-specific factors to ensure individualized care. This study examines clinical parameters that influence ITB recommendations, evaluates their adherence to guidelines, and assesses their impact on patient survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In a retrospective analysis, data from 187 mCRPC patients discussed at an ITB in a tertiary care center in 2018 were evaluated. Patient- and disease-specific factors were correlated with adherence to National Comprehensive Cancer Network<jats:sup>\u00ae<\/jats:sup> (NCCN<jats:sup>\u00ae<\/jats:sup>) guidelines and overall survival (OS). The impact of clinical parameters on survival outcomes was assessed through univariate and multivariate analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The median patient age was 72.8\u00a0years, with a median prostate-specific antigen (PSA) level of 65.0\u00a0ng\/ml. Guideline-compliant recommendations were given in 42.9% of cases, while 57.1% received individualized recommendations. Clinical trial eligibility was noted in 24.8% of patients. Individualized ITB recommendations were associated with significantly longer OS (38.3 vs. 21.2\u00a0months, p\u2009=\u20090.03). Shorter OS correlated with renal impairment (p\u2009=\u20090.007), symptomatic metastases (p\u2009&lt;\u20090.0001), and visceral metastases (p\u2009&lt;\u20090.0001). Limitations include the retrospective design, lack of follow-up on therapy adherence, and absence of progression-free survival (PFS) data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>ITB discussions improve survival in mCRPC patients, mainly due to personalized approaches and better access to clinical trials. Visceral and symptomatic metastases as well as renal impairment are risk factors for reduced OS, emphasizing the need for careful management of these high-risk patients. The results support the expanded use of ITB to improve mCRPC treatment outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00432-025-06135-8","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T07:40:14Z","timestamp":1741246814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of interdisciplinary tumor boards (ITB) and personalized treatment on survival outcomes in metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"151","author":[{"given":"Laura","family":"Lawaczeck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"R\u00fcdiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Hennenlotter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00ebl","family":"Hammes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Spingler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Walz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Erne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Tsaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"22","key":"6135_CR1","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.3390\/cancers13225723","volume":"13","author":"S Asif","year":"2021","unstructured":"Asif S, Teply BA (2021) Biomarkers for treatment response in advanced prostate cancer. Cancers (Basel) 13(22):5723","journal-title":"Cancers (Basel)"},{"issue":"3","key":"6135_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/1754-9485.12851","volume":"63","author":"D Atwell","year":"2019","unstructured":"Atwell D et al (2019) Referral rates to multidisciplinary team meetings: Is there disparity between tumour streams? J Med Imaging Radiat Oncol 63(3):378\u2013382","journal-title":"J Med Imaging Radiat Oncol"},{"key":"6135_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7267083","author":"A Bednarek","year":"2020","unstructured":"Bednarek A et al (2020) Limitations of systemic oncological therapy in breast cancer patients with chronic kidney disease. J Oncol. https:\/\/doi.org\/10.1155\/2020\/7267083","journal-title":"J Oncol"},{"issue":"4","key":"6135_CR4","first-page":"306","volume":"28","author":"MJ Boyer","year":"2014","unstructured":"Boyer MJ, Salama JK, Lee WR (2014) Palliative radiotherapy for prostate cancer. Oncology (Williston Park) 28(4):306\u2013312","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"6135_CR5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clgc.2019.03.020","volume":"17","author":"J Budnik","year":"2019","unstructured":"Budnik J et al (2019) Prognostic significance of sites of visceral metastatic disease in prostate cancer: a population-based study of 12,180 patients. Clin Genitourin Cancer 17(4):260\u2013267","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"6135_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.12998\/wjcc.v8.i1.54","volume":"8","author":"PF Cui","year":"2020","unstructured":"Cui PF et al (2020) Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: a study of 1358 patients. World Journal of Clinical Cases 8(1):54\u201367","journal-title":"World Journal of Clinical Cases"},{"issue":"22","key":"6135_CR7","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382(22):2091\u20132102","journal-title":"N Engl J Med"},{"key":"6135_CR8","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2014.34.e461","author":"NS El Saghir","year":"2014","unstructured":"El Saghir NS et al (2014) Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide. Am Soc Clin Oncol Educ Book. https:\/\/doi.org\/10.14694\/EdBook_AM.2014.34.e461","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"6135_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","volume":"185","author":"S Gillessen","year":"2023","unstructured":"Gillessen S et al (2023) Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer 185:178\u2013215","journal-title":"Eur J Cancer"},{"key":"6135_CR10","unstructured":"EAU Guidelines. Edn. Presented at the EAU Annual Congress Milan 2023. ISBN 978\u201394\u201392671\u201319\u20136."},{"issue":"7\u20138","key":"6135_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000500426","volume":"42","author":"A Heidenreich","year":"2019","unstructured":"Heidenreich A (2019) Multidisciplinary team meetings for prostate cancer treatment: we can do much better in daily life. Oncol Res Treat 42(7\u20138):363\u2013364","journal-title":"Oncol Res Treat"},{"key":"6135_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-023-01033-x","author":"J Heilinger","year":"2023","unstructured":"Heilinger J et al (2023) Threshold for defining PSMA-positivity prior to Lu-PSMA therapy: a comparison of [Ga]Ga-PSMA-11 and [F]F-DCFPyL in metastatic prostate cancer. Ejnmmi Res. https:\/\/doi.org\/10.1186\/s13550-023-01033-x","journal-title":"Ejnmmi Res"},{"issue":"3","key":"6135_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/jnci\/djad268","volume":"116","author":"RS Huang","year":"2024","unstructured":"Huang RS et al (2024) The impact of multidisciplinary cancer conferences on overall survival: a meta-analysis. Jnci-J Natl Cancer Inst 116(3):356\u2013369","journal-title":"Jnci-J Natl Cancer Inst"},{"issue":"4","key":"6135_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","volume":"26","author":"SJ Keam","year":"2022","unstructured":"Keam SJ (2022) Lutetium Lu 177 Vipivotide Tetraxetan: first approval. Mol Diagn Ther 26(4):467\u2013475","journal-title":"Mol Diagn Ther"},{"issue":"4","key":"6135_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000091","volume":"1","author":"V Launay-Vacher","year":"2016","unstructured":"Launay-Vacher V, Janus N, Deray G (2016) Renal insufficiency and cancer treatments. ESMO Open 1(4):e000091","journal-title":"ESMO Open"},{"issue":"1","key":"6135_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","volume":"21","author":"J Mateo","year":"2020","unstructured":"Mateo J et al (2020) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 21(1):162\u2013174","journal-title":"Lancet Oncol"},{"issue":"5","key":"6135_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler JL et al (2019) Prostate cancer, version 2.2019, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw 17(5):479\u2013505","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"6135_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3390\/biomedicines10030689","volume":"10","author":"J Morote","year":"2022","unstructured":"Morote J et al (2022) Definition of castrate resistant prostate cancer: new insights. Biomedicines 10(3):689","journal-title":"Biomedicines"},{"key":"6135_CR19","unstructured":"NCCN\u00ae, NCCN\u00ae Guidelines Version 3.2022 Prostate Cancer, Systemic therapy for M1 CRPC. 2022."},{"key":"6135_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-015-0495-4","author":"S Nilsson","year":"2016","unstructured":"Nilsson S (2016) Radionuclide therapies in prostate cancer: integrating radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer. Current Oncology Reports. https:\/\/doi.org\/10.1007\/s11912-015-0495-4","journal-title":"Current Oncology Reports"},{"key":"6135_CR21","first-page":"117","volume":"5","author":"CJ Paller","year":"2011","unstructured":"Paller CJ, Antonarakis ES (2011) Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug des Devel Ther 5:117\u2013124","journal-title":"Drug des Devel Ther"},{"key":"6135_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100020","volume":"2","author":"B Papotti","year":"2021","unstructured":"Papotti B et al (2021) Drug-drug interactions in polypharmacy patients: the impact of renal impairment. Curr Res Pharmacol Drug Discov 2:100020","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"2","key":"6135_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100431","volume":"7","author":"G Procopio","year":"2022","unstructured":"Procopio G et al (2022) Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study. ESMO Open 7(2):100431","journal-title":"ESMO Open"},{"issue":"6","key":"6135_CR24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5489\/cuaj.10167","volume":"4","author":"F Saad","year":"2010","unstructured":"Saad F, Hotte SJ (2010) Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J 4(6):380\u2013384","journal-title":"Can Urol Assoc J"},{"issue":"9","key":"6135_CR25","doi-asserted-by":"publisher","first-page":"E415","DOI":"10.5489\/cuaj.5154","volume":"12","author":"F Saad","year":"2018","unstructured":"Saad F et al (2018) Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: expert opinion and review of the evidence. Can Urol Assoc J 12(9):E415\u2013E420","journal-title":"Can Urol Assoc J"},{"issue":"12","key":"6135_CR26","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091\u20131103","journal-title":"N Engl J Med"},{"issue":"6","key":"6135_CR27","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41416-021-01663-9","volume":"126","author":"PHJ Slootbeek","year":"2022","unstructured":"Slootbeek PHJ et al (2022) Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. Br J Cancer 126(6):907\u2013916","journal-title":"Br J Cancer"},{"issue":"1","key":"6135_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12913-020-4930-3","volume":"20","author":"ML Specchia","year":"2020","unstructured":"Specchia ML et al (2020) The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res 20(1):73","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"6135_CR29","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41391-021-00318-3","volume":"24","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST et al (2021) Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis 24(4):1032\u20131040","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6135_CR30","unstructured":"Tappero S, et al. (2023) Overall survival of metastatic prostate cancer patients according to location of visceral metastatic sites. Clinical Genitourinary Cancer."},{"key":"6135_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/EDBK_156686","volume":"35","author":"JM Unger","year":"2016","unstructured":"Unger JM et al (2016) The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book 35:185\u2013198","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"6135_CR32","first-page":"3101","volume":"45","author":"ECA van der Sar","year":"2023","unstructured":"van der Sar ECA et al (2023) Lutetium-177 PSMA for prostate cancer; current developments and challenges. TvNG 45(2):3101\u20133109","journal-title":"TvNG"},{"issue":"5","key":"6135_CR33","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/annonc\/mdv029","volume":"26","author":"RWF van Leeuwen","year":"2015","unstructured":"van Leeuwen RWF et al (2015) Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol 26(5):992\u2013997","journal-title":"Ann Oncol"},{"issue":"11 Suppl","key":"6135_CR34","first-page":"23","volume":"10","author":"RJ Winn","year":"1996","unstructured":"Winn RJ, Botnick W, Dozier N (1996) The NCCN guidelines development program. Oncology (Williston Park) 10(11 Suppl):23\u201328","journal-title":"Oncology (Williston Park)"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06135-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06135-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06135-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T14:25:17Z","timestamp":1744640717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06135-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["6135"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06135-8","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"1 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted using retrospective analysis of patient data. Formal ethics approval was obtained from the Ethical Committee of the University of T\u00fcbingen (922\/2020BO2), and the need for informed consent was waived due to the retrospective nature of the study, in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"101"}}